CLINICAL_TRIALS
trial_result
· 2021-03-26
Clinical Trial Update: Ustekinumab (STELARA) for the Treatment of Active Sight-Threatening Uveitis (STAR Study) [Phase 2]
Summary
Phase 2 trial evaluating ustekinumab (Stelara) for active sight-threatening uveitis has completed with posted results.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: National Eye Institute (NEI) | Conditions: Uveitis | Phase 2 | Status: COMPLETED | Results posted: 2021-03-26